Stifel Nicolaus Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “buy” rating reiterated by investment analysts at Stifel Nicolaus in a note issued to investors on Friday. They currently have a $222.00 price target on the stock, up from their previous price target of $220.00. Stifel Nicolaus’ price target suggests a potential upside of 32.90% from the company’s current price.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.26% on Friday, hitting $167.04. The stock had a trading volume of 1,176,719 shares. Alexion Pharmaceuticals has a 52-week low of $100.89 and a 52-week high of $185.43. The stock has a 50-day moving average of $163.0 and a 200-day moving average of $159.3. The company has a market cap of $33.040 billion and a price-to-earnings ratio of 101.26.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 24th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter last year, the company posted $0.73 earnings per share. Alexion Pharmaceuticals’s revenue was up 38.5% compared to the same quarter last year. On average, analysts predict that Alexion Pharmaceuticals will post $4.94 earnings per share for the current fiscal year.
ALXN has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday. They now have a $220.00 price target on the stock, up previously from $210.00. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note on Friday. They now have a $179.00 price target on the stock, up previously from $174.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note on Friday. They now have a $176.00 price target on the stock. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $183.00.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.